Trials / Completed
CompletedNCT00046800
Study of OSI-211 vs. Topotecan in Patients With Relapsed Epithelial Ovarian Cancer
A Randomized, Open Label Phase II Study of OSI-211 vs Topotecan in Patients With Advanced and/or Recurrent Epithelial Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 80 (planned)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to estimate the efficacy and safety of OSI-211 and topotecan in patients with relapsed epithelial ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | OSI-211 (Liposomal Lurtotecan) |
Timeline
- Start date
- 2002-09-01
- Completion
- 2003-03-01
- First posted
- 2002-10-04
- Last updated
- 2011-10-20
Locations
11 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00046800. Inclusion in this directory is not an endorsement.